SB Pursuing Paxil Claims For Long- And Short-Term Use In Generalized Anxiety
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
SmithKline Beecham is planning to follow up its pending supplemental NDA for short-term use of Paxil (paroxetine) in the treatment of generalized anxiety disorder (GAD) with an sNDA for long-term use.